VANCOUVER, British Columbia, May 1, 2015 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), today announced that Mr. Pat Higgins, Tekmira's Chief Operating Officer and Dr. William Symonds, Tekmira's Chief Development Officer will participate in an analyst-led fireside chat at the 40 th Annual Deutsche Bank Health Care Conference on Thursday, May 7, 2015 at 8.20am-8.55am (PT) / 11.20am-11.55am (ET) at the InterContinental Boston Hotel, Boston, MA.

Webcast Information

A live webcast of the event will be available on the Investors section of the company's website at www.tekmira.com. A webcast replay of the presentation will be available on the Tekmira website within 24 hours following the event.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV). Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence. Our portfolio of assets includes eight drug candidates for use in combination to develop a cure for HBV, and includes our product TKM-HBV currently in Phase 1 clinical studies.

We also have a pipeline of non-HBV assets in oncology, anti-viral and metabolic therapeutics that leverage our expertise in RNA interference (RNAi) therapeutics and leading Lipid Nanoparticle (LNP) technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body's own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell. We intend to maximize the value of our non-HBV assets in the clinic, namely: TKM-PLK1 for advanced gastrointestinal neuroendocrine tumors, adrenocortical carcinoma and hepatocellular carcinoma; and TKM-Ebola, and TKM-Ebola-Guinea for ebola virus disease; as well as our preclinical programs in metabolic disorders and filoviruses.

Tekmira is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.tekmira.com.

CONTACT: Investors         Adam Cutler         Senior Vice President, Corporate Affairs         Phone: 604.419.3200         Email:acutler@tekmira.com                  Julie P. Rezler         Director, Investor Relations and Corporate Communications         Phone: 604-419-3200         Email: jrezler@tekmira.com                  Media         Please direct all media inquiries to: media@tekmira.com

Tekmira Pharmaceuticals logo